Perl, Alexander E.
Hosono, Naoko http://orcid.org/0000-0002-6336-3250
Montesinos, Pau http://orcid.org/0000-0002-3275-5593
Podoltsev, Nikolai http://orcid.org/0000-0002-3657-778X
Martinelli, Giovanni http://orcid.org/0000-0002-1025-4210
Panoskaltsis, Nicki http://orcid.org/0000-0001-8972-5697
Recher, Christian
Smith, Catherine C. http://orcid.org/0000-0003-0160-7026
Levis, Mark J. http://orcid.org/0000-0003-0473-6982
Strickland, Stephen http://orcid.org/0000-0002-6861-2041
Röllig, Christoph http://orcid.org/0000-0002-3791-0548
Groß-Langenhoff, Marco
Chou, Wen-Chien http://orcid.org/0000-0003-2967-698X
Lee, Je-Hwan http://orcid.org/0000-0002-7060-1675
Yokoyama, Hisayuki
Hasabou, Nahla
Lu, Qiaoyang
Tiu, Ramon V.
Altman, Jessica K.
Funding for this research was provided by:
Astellas Pharma US
Astellas Pharma
Article History
Received: 10 December 2021
Revised: 15 April 2022
Accepted: 9 May 2022
First Online: 30 May 2022
Competing interests
: AE Perl reports grants, personal fees and non-financial support from Astellas, during the conduct of the study; grants, personal fees, and non-financial support from FujiFilm; grants, personal fees, and non-financial support from Daiichi Sankyo; grants and personal fees from Abbvie and Actinium Pharmaceuticals; personal fees from Agios, Loxo, LLS/Beat AML, and Forma; non-financial support from Arog; personal fees and non-financial support from New Link Genetics, Novartis, Takeda, and Jazz; and grants from Bayer and Biomed Valley Discoveries, outside the submitted work. N Hosono reports no relevant conflicts of interest to disclose. P Montesinos reports research support from Pfizer, Abbvie, and Daiichi Sankyo; consultancy from Celgene, Pfizer, and Abbvie; and speakers bureau from Astellas, Novartis, and Janssen. N Podoltsev reports consultancy fees from Pfizer, Celgene, Agios Pharmaceuticals, Blueprint Medicines, Incyte, Novartis, Bristol-Myers Squibb, CTI Biopharma, PharmaEssentia, Constellation Pharmaceuticals, Cogent BioSciences, and AbbVie; and institutional research funding from Pfizer, Celgene, CTI Biopharma, Boehringer Ingelheim, Astellas, Daiichi Sankyo, Sunesis Pharmaceuticals, Jazz Pharmaceuticals, Astex Pharmaceuticals, Genentech, AI Therapeutics, Samus Therapeutics, Arog Therapeutics, and Kartos Therapeutics. G Martinelli reports grant funding and consultancy fees from Amgen, Ariad, Incyte, Pfizer, Roche, Celgene, Janssen, AbbVie, and Novartis. N Panoskaltsis reports no relevant conflicts of interest to disclose. C Recher reports grant funding and personal fees from Celgene, Sunesis, Amgen, and Novartis and personal fees from Incyte, Jazz Pharmaceuticals, AbbVie, Astellas, Macrogenics, and Otsuka. C Smith reports research funding from Abbvie, Revolution Medicines, Celgene, FujiFilm; consulting fees from Astellas, Daichi Sanyko, and Genentech to attend an advisory board meeting; and reports being a stockolder at Ligacept, LLC. MJ Levis reports grants and personal fees from Astellas and FujiFilm and personal fees from Daiichi Sankyo, Amgen, and Menarini. S Strickland reports consulting or advisory fees from Abbvie, Astellas Pharma, Jazz Pharmaceuticals, Kite, a Gilead company, Novartis, and Pfizer and research funding at an institutional level from Abbvie, Astellas Pharma, Inc, Celator/Jazz, Celgene, Daiichi Sankyo, Karyopharm Therapeutics, Menarini, Novartis, and Sunesis Pharmaceuticals. C Röllig has received grants from AbbVie, Novartis, and Pfizer; consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Janssen, Jazz, Novartis, Pfizer, and Roche; and honoraria for speaker engagements from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Janssen, Jazz, Novartis, Pfizer, and Roche. WC Chou reports no relevant conflicts of interest to disclose. H Lee has received honoraria for speaker engagements from AbbVie Korea and Astellas Korea, participated in and advisory board for AbbVie and Astellas, and is President of The Korean Society of Hematology. H Yokoyama reports having received honoraria from Astellas for speaking engagements. Q Lu, N Hasabou, M Groß-Langenhoff are employees of Astellas. R Tiu is a former employee of Astellas. JK Altman reports advisory or consulting fees from AbbVie, Amgen, Astellas, Daiichi Sankyo, Kura Oncology, Syros, and Theradex; institutional research funding for trials conducted by ALX Oncology, Amgen, Aptos, Astellas, Aprea, BioSight, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, FujiFilm, Immunogen, Kartos, Kura Oncology, and Loxo; reimbursement for travel from BioSight; and serves on a data monitoring committee for GlycoMimetics.